Home › Cancro al seno triplo negativo › Minnesota › Rochester
Studi clinici su Cancro al seno triplo negativo a Rochester, MN
11 studi su Cancro al seno triplo negativo cercano partecipanti presso sedi a Rochester e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
PRE-ISPY Phase I/II Oncology Platform Program
In reclutamentoFase 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
In reclutamento
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
In reclutamentoStudio osservazionale
- Mayo Clinic Rochester, Rochester
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
In reclutamentoFase 2
- Mayo Clinic, Rochester
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic, Rochester
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
In reclutamentoFase 3
- Mayo Clinic Rochester, Rochester
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
In reclutamentoFase 1
- Mayo Clinic Rochester, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic - Rochester, Rochester
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
In reclutamentoFase 1
- Mayo Clinic Rochester, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
In reclutamentoFase 2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
In reclutamentoFase 1/2
- Mayo Clinic, Rochester
Studi su Cancro al seno triplo negativo in altre città
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Altri studi a Rochester
- Cancro al seno42 studi
- Cancro del polmone non a piccole cellule37 studi
- Cancro metastatico31 studi
- Cancro (tutti i tipi)30 studi
- Cancro ovarico29 studi
- Cancro colorettale29 studi
- Mieloma multiplo24 studi
- Insufficienza cardiaca22 studi
- Cancro alla prostata22 studi
- Cancro pancreatico22 studi
- Cancro dell'endometrio20 studi
- Cancro ai polmoni20 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.